MedTrace Logo

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

NCT05714072 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-11-18

No results posted yet for this study

Summary

The study is being done to see if the combination of ruxolitinib and abemaciclib is a safe and effective treatment for people with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Conditions

  • Myelofibrosis Due to and Following Polycythemia Vera

Interventions

DRUG

Ruxolitinib

10mg BID or 15mg BID

DRUG

Abemaciclib

50, 100 and 150 mg

Sponsors & Collaborators

Principal Investigators

  • Raajit Rampal · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-25
Primary Completion
2027-01-31
Completion
2027-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05714072 on ClinicalTrials.gov